HIGH RESOLUTION ELECTRON MICROSCOPY FACILITY (HREMF) The mission of the High Resolution Electron Microscopy Facility (HREMF) is to provide high-quality, affordable electron microscopy services to research investigators at MD Anderson Cancer Center. The facility is in the Smith Research Building and houses a JEOL JEM 1010 transmission electron microscope, a JEOL JSM 5900 scanning electron microscope, a TechnoTrade coating system, a Leica ultramicrotome, and a Leica ultrastainer. Dr. Robert Langley has directed the HREMF for the past 10 years and has 20 years of experience in microscopic imaging of tissues and cells. Kenneth Dunner, Jr, is the manager of the HREMF and is responsible for the daily operations of the facility, including processing and imaging of samples. The HREMF houses the only scanning electron microscope on campus and the only transmission electron microscope that is dedicated to research applications. Since its inception in 1997, the HREMF has received approximately $500,000 in capital equipment funds from MD Anderson. In grant Yr42, 89% of the total usage of the HREMF was by peer-reviewed funded faculty, and we are requesting 55% of the HREMF budget from the CCSG ($106,740). During the past 6 years, the HREMF has provided 6759 hours of service to 164 investigators, 132 of whom were cancer center members representing all 16 CCSG programs. Usage was well distributed among the CCSG programs, and no program accounted for more than 15% of the HREMF's resources. The facility also ranked near the top of a user satisfaction survey and made regular contributions to high-impact publications. The HREMF contributed to 124 publications in peer-reviewed journals, with 88 publications (71%) in journals with IF >5 and 31 publications (25%) in journals with IF >10, including Nature (5 articles), Nat Cell Biol (3 articles), Nat Commun (2 articles), Cancer Cell, Nat Immunol, and Nat Nanotechnol. The HREMF's Specific Aims are:
Aim 1 : To provide MD Anderson Cancer Center investigators with access to microscopy instruments necessary to perform research at the ultrastructural level.
Aim 2 : To provide complete electron microscopy specimen preparation services.
Aim 3 : To provide technical assistance and consultation for electron microscopy applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-43
Application #
9794662
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications